NFKB1 and Miyoshi myopathy: CTZ dose-dependently decreased the levels of phosphorylated p65 (with a maximal decrease of 0.3-fold in MM.1S cells and 0.2-fold in NCI-H929 cells) and phosphorylated IκBα (with a maximal increase of 0.3-fold in MM.1S cells and 0.4-fold in NCI-H929 cells) compared with the control, suggesting its inhibition of the NF-κB pathway in MM cells (Fig. 5b,d).